Zydus Cadila First Off The Block In NASH After India Approval
US Phase III Trials To Begin Q2 FY21
Cadila Healthcare has received the first approval globally, in India, for a NASH therapy, after the national regulator cleared its candidate saroglitazar. The company also expects to begin Phase III trials in the US in the second quarter of fiscal 2021.
